Pomegraundefined
- Oura and existing shareholders seek up to $2.2 billion through 50 million shares priced $40-$44, with trading expected the week of September 28.
- Nine-month revenue through June 30 reached $1.21 billion, up 74% year over year; net income surged to $60.8 million from $1.5 million.
- The company projects 5.7 million paid members by year-end, representing 96% annual growth, as it repositions from device-maker to health-data platform.
Finnish smart ring maker Oura Inc. launches its Nasdaq roadshow at $40-$44 per share, targeting a $15.62 billion valuation underpinned by 74% revenue growth to $1.21 billion through June.
Lead
What Makes Oura Worth $15.6 Billion?
The revenue trajectory makes the clearest case. For the nine months ended June 30, 2026, Oura generated $1.21 billion in total revenue, up 74% from $697.6 million a year earlier. Net income for the same period reached $60.8 million, compared with $1.5 million in the prior year - a near-40-fold improvement that demonstrates the operating leverage embedded in its business model as hardware costs stabilize and software revenue expands.
Central to the valuation argument is the subscription layer. Membership software revenue grew 121% year over year to $240.5 million for the nine-month period, carrying an 89% gross margin - a profile more characteristic of enterprise software than consumer electronics. Member retention reinforces the platform thesis: 80% of subscribers renew after the first year, generating predictable recurring cash flow that commands a higher earnings multiple.
The company ended June 30 with five million paid members, double the figure from twelve months earlier, and Chief Executive Officer Tom Hale has guided for close to $2 billion in full-year 2026 revenue. Oura expects to close the fiscal year with approximately 5.7 million subscribers, representing 96% annual growth.
How to Buy the Oura IPO
Institutional investors participating in the roadshow will receive allocations at the final offering price, which is expected during the week of September 28. Retail investors can purchase OURA shares through standard brokerage accounts once the stock begins trading on Nasdaq. The offering is predominantly secondary - 73% of shares come from existing shareholders rather than the company's treasury - meaning the majority of proceeds flow to early backers rather than funding Oura's operations directly.
Platform Repositioning
Oura's prospectus frames the company not as a hardware vendor but as a health-data platform that monetizes continuous biosensing through software subscriptions. The device logs heart rate variability, sleep stages, skin temperature, activity levels, fertility windows, and metabolic health indicators, feeding a member dashboard and third-party integrations that provide recurring revenue with near-software-level margins.
The strategy mirrors a broader pattern in consumer technology: use a physical device as the data-collection layer and build durable economics on top of the resulting data relationships. With 89% gross margins on its membership tier, Oura has more in common structurally with software-as-a-service businesses than with wearable rivals who rely on hardware refresh cycles.
Competitive and Market Context
Oura enters the public market with Apple (AAPL) and Samsung both accelerating competing form factors, including smartwatches and their own ring hardware initiatives. Against that backdrop, the IPO tests whether investors will assign platform multiples to a company whose addressable market is, for now, defined by a single physical product category.The listing also arrives as rising bond yields and uncertainty around Federal Reserve rate policy have compressed valuations for long-duration growth equities in recent weeks, adding an additional layer of market sensitivity to the roadshow reception.
Outlook
Oura's pricing range implies a multiple well above comparable consumer hardware companies, a gap that management's $2 billion 2026 revenue projection and 89% subscription gross margins are intended to justify. With trading expected the week of September 28, the offering will serve as a live read on institutional appetite for health-data platforms at scale - and a potential bellwether for the broader autumn IPO calendar.